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Context 
The cervical screening programmes in the UK and the Netherlands are replacing cytology 
by human papillomavirus (HPV) testing. In the Netherlands women will be screened 
routinely at ages 30, 35, 40, 50 and 60 years. In the UK a decision on screening frequency 
has yet to be made by the National Screening Committee. Currently British women are 
screened with cytology every 3 years at ages 25-49 and every 5 years at ages 50-64. 
Pooled results of four randomised controlled trials in Europe showed that HPV testing 
reduces cervical cancer risk1, and the British ARTISTIC trial2 and several other studies 
have also shown that it gives longer protection for cervical intraepithelial neoplasia grade 
3 (CIN3).  
 
Methods 
Dijkstra and colleagues describe the 14 year follow-up of the POBOSCAM trial in the 
Netherlands over 3 rounds of cervical screening with a 5 year interval. Almost 45,000 
women were randomised in 1999-2002 between cytology alone and cytology plus HPV 
testing. This report compares CIN3 and cervical cancer rates in women who were HPV 
negative in the intervention arm and those who were cytology negative in the control arm.  
 
Findings 
The cumulative risks of CIN3 and invasive cancer were similar after 14 years in women 
who were HPV negative and after 9 years in women who were cytology negative. The 
CIN3 rate was higher in women aged 30-39, but the authors conclude that their results 
support the decision to extend the routine screening interval in women aged over 40 from 
the current 5 years with cytology to 10 years with HPV testing. They note that invasive 
cancer showed the opposite trend with age, and emphasise the need to keep the 
screening interval under review when HPV screening has been rolled out nationally. 
 
Commentary  
Among women testing negative for HPV at age 30 or over the 14 year cumulative rates 
for CIN3+ (CIN3 or cancer: 0.56%, 95% CI 0.45%-0.70%) and for invasive cancer alone 
(0.09%, 95% CI 0.04%-0.18%) are both extremely low. The primary aim of cervical 
screening is to prevent cancer, and the 22 cancers observed among HPV negative women 
in this very large study, suggesting an invasive cancer risk of the order of 1 in 1,000 after 
a 10 year screening interval, are a major addition to the evidence. Cervical cancer deaths 
are so rare in screened women that the effect on mortality of a longer screening interval 
can be estimated only by modelling and extrapolation. Most cancers caused by 
subsequent HPV infection will develop towards the end of the interval due to the lag from 
infection and CIN3 development to malignancy. These are likely to be diagnosed at an 
early stage even with a 10-year interval. Cancers present at the time of the negative HPV 
test would be at higher risk of being advanced or metastatic 10 years later, although 
modern HPV tests may already be sensitive enough to prevent most of this small but 
serious hazard. Collaborative pooling of data and modelling studies are needed to 
estimate the effects on early and advanced cancer incidence of HPV testing with 
screening intervals of up to 10 years at different ages, and particularly at a woman’s final 
HPV test. CIN3+ is rare in women aged over 50 but a higher proportion are invasive 
cancers. The age range in POBOSCAM was 29-61 so the British protocol for women aged 
below 30 will depend largely on updated results of the ARTISTIC trial, which included 
women from age 20.  
 
Implications for practice 
A 10-year HPV screening interval may be safe above age 40 or even 30, but the age at 
first HPV test and the screening interval in younger women must take into account their 
high HPV prevalence and CIN3 rate. In the UK the CIN3 rate at age 25-29 is 9 times higher 
than at 40-49. HPV infection is common among teenagers, and CIN3 detected at age 25 
may have remained undiagnosed for up to 10 years. 
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